Click on headlines below to download research

Strong rebound for established specialist
BB Biotech | 27/02/2017

BB Biotech (BION) is a long-established investor in biotech innovation, offering access to a concentrated portfolio of c 30 companies covering a range…

Another strong year expected
SinnerSchrader | 02/02/2017

The Q1 results point to another year of solid revenue growth and further EBITA margin expansion. While SinnerSchrader’s P/E rating has caught up…

Increased scale offers greater opportunities
Deutsche Beteiligungs | 31/01/2017

FY16 proved to be a significant year for Deutsche Beteiligungs (DBAG). In addition to generating strong NAV returns and maintaining an elevated level of…

Termination of coverage
PSI Group | 23/01/2017

Edison Investment Research is terminating coverage on PSI (PSAN). Please note you should no longer rely on any previous research or estimates for this…

A cloudier picture
Evolva | 16/01/2017

The much-awaited stevia update has confirmed that EverSweet is still on track to be launched in 2018, and there is a new production plan. That said, talks…

Continuing to take steps to focus on core
Medigene | 21/12/2016

Medigene has announced that it has granted an exclusive worldwide licence for the development and commercialisation of its preclinical-stage adeno-associated…

First patient enrolled in pivotal RESMAIN study
4SC | 19/12/2016

4SC has announced the enrolment of the first patient in its RESMAIN study. This is a pivotal study to evaluate resminostat (RES), an epigenetic cancer…

Termination of coverage
Stratec Biomedical | 13/12/2016

Edison Investment Research is terminating coverage on Stratec Biomedical (SBS). Please note you should no longer rely on any previous research or estimates…

Dividend increased 67%
SinnerSchrader | 28/11/2016

SinnerSchrader (SZZ) expects another year of double-digit revenue growth and margin improvement in FY17, underpinned by the Audi win. This confidence is…

Potential for further outperformance
HBM Healthcare Investments | 21/11/2016

HBM Healthcare Investments (HBMN) is a Switzerland-listed closed-end fund investing in listed and private healthcare companies globally. In a volatile…

One hand on the prize
Paion | 21/11/2016

Paion has reported positive data from the first pivotal US study of its ultra-short-acting sedative remimazolam in procedural sedation. Induction and recovery…

Progression of LOQTEQ portfolio
aap Implantate | 21/11/2016

Q316 results highlighted a challenging quarter despite being broadly in line with company guidance (sales of €2.9m and an EBITDA loss of €1.8m).…

Q3 organic growth remains robust at 12%
GFT | 15/11/2016

Q3 numbers were in line with expectations and management has maintained both its FY16 and long-term guidance. The backdrop remains broadly unchanged, with…

Financed to inflection points
Mologen AG | 14/11/2016

The recent completion of the €13.6m capital raise and the soon to be issued convertible bond of presumably €2.5m will enable Mologen, alongside…

Q316 results and business update
Epigenomics | 11/11/2016

Epigenomics continues to execute on the commercial front. The US is now the main market for Epi proColon, the only FDA-approved, blood-based colorectal…

Well placed in a dynamic sector
SinnerSchrader | 10/11/2016

SinnerSchrader (SZZ) reported a solid finish to an excellent financial year, which saw double-digit growth in underlying revenues and EBIT margin expansion.…

Two steps forward one step back
PSI | 10/11/2016

PSI’s underwhelming financial performance and lower revenue guidance for FY16 reflect difficult trading conditions as well as retaining price discipline…

Consulting and IT services for banks
GFT | 10/11/2016

GFT is building a global IT services and consulting business, focused on the growing opportunity in the financial services sector. It is diversifying geographically…

Bigger, stronger, faster
Sygnis | 09/11/2016

Following the acquisition of Expedeon, Sygnis expects to achieve profitability in 2017 if sales grow to about €7m; management is focused on achieving…

Digesting acquisitions after Chinese hiccup
Stratec Biomedical | 09/11/2016

Stratec, a designer and builder of automated OEM diagnostic systems made two acquisitions during 2016. The first (from April), was Diatron, a leading Hungarian…

Phase III confirms remimazolam saves time
Paion | 09/11/2016

Paion has reported positive results from the first pivotal US study of its ultra-short-acting sedative remimazolam in procedural sedation. Induction and…

Back on track
Newron Pharmaceuticals | 09/11/2016

Xadago (safinamide) for Parkinson’s disease (PD) is back on track in the US as the FDA has informed the company and its partners, Zambon and US WorldMeds,…

Partnered and proprietary success
MorphoSys | 09/11/2016

Top-line clinical data from the 837-person Phase III trial of Guselkumab for the treatment of plaque psoriasis was recently released by MorphoSys’s…

'Next Level' on track
Mologen | 09/11/2016

Mologen are focused on the development and commercialisation of lead candidate lefitolimod (oncology and HIV) and the next-generation molecules EnanDIM…

Steady progress on defined strategy
MagForce AG | 09/11/2016

MagForce is moving forward with its strategy to drive uptake and acceptance of its NanoTherm nanoparticle-based therapy for cancer. The first NanoActivator…